دورية
Safety, tolerability, and activity of the active C1s antibody riliprubart in cold agglutinin disease: a phase 1b study
| العنوان: | Safety, tolerability, and activity of the active C1s antibody riliprubart in cold agglutinin disease: a phase 1b study |
|---|---|
| المؤلفون: | D’Sa, Shirley, Vos, Josephine M. I., Barcellini, Wilma, Wardęcki, Marek, Perrin, Laurent, Barker, Graham, Zilberstein, Moshe, Storek, Michael, Chow, Timothy, Röth, Alexander |
| المصدر: | Blood; February 2024, Vol. 143 Issue: 8 p713-720, 8p |
| مستخلص: | •Riliprubart (SAR445088, BIVV020) was generally well tolerated in patients with cold agglutinin disease.•A single dose led to complement pathway inhibition, control of hemolysis, and improvement in anemia, sustained over 15 weeks. |
| قاعدة البيانات: | Supplemental Index |
| تدمد: | 00064971 15280020 |
|---|---|
| DOI: | 10.1182/blood.2023022153 |